Psychedelic-assisted therapy: An overview for the internist
Cleveland Clinic Journal of Medicine March 1, 2025 Franklin King, Brian S. Barnett, Erin E. Mauney 11 citations
Psychedelic-assisted therapy, using substances like MDMA and psilocybin, shows preliminary efficacy for depression, PTSD, and substance use disorders. Psilocybin, MDMA, and LSD have been designated breakthrough therapies by the FDA. However, in August 2024, the FDA declined to approve MDMA and requested an additional phase 3 trial. Clinicians should prepare for the possible return of psychedelics to medicine.